Research programme: monomethyl fumarate prodrugs - Alkermes plc

Drug Profile

Research programme: monomethyl fumarate prodrugs - Alkermes plc

Alternative Names: AKLS-MMF; ALKS MMF; MMF prodrug program - Alkermes; RDC-1559

Latest Information Update: 19 Jul 2013

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Fumarates; Small molecules
  • Mechanism of Action Immunomodulators; NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple sclerosis

Most Recent Events

  • 17 Jul 2013 Preclinical trials in Multiple sclerosis in Ireland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top